



September 30, 2005  
NRC:05:057

Document Control Desk  
U.S. Nuclear Regulatory Commission  
Washington, D.C. 20555-0001

### **Evaluation of a Deviation in Pump Seizure Analysis**

A deviation was determined to exist in the pump seizure analysis for the Susquehanna Units 1 and 2 based on information provided by the licensee, PPL. It was determined on September 20, 2005 that Framatome ANP did not have sufficient information to determine if this deviation represents a defect and the licensee was informed of this on September 23, 2005.

Framatome ANP performs analyses for the pump seizure event to support reload licensing for the Susquehanna units. The Framatome ANP pump seizure analyses performed for Susquehanna include calculations to determine how many rods fail during the event and calculations to determine the dose consequences from the calculated number of failed fuel rods. One assumption used in the dose calculation is that the condenser leakage rate to the environment is 1% per day. On August 12, 2005, PPL notified FANP by letter and in a subsequent phone call that the 1% per day condenser leakage rate was not appropriate for Susquehanna Units 1 and 2.

PPL performed an operability assessment for the issue and concluded that no operability concerns exist and no immediate actions were required. Framatome ANP concurs with the PPL assessment based on other industry assessments of the pump seizure event. However, Framatome ANP has not performed any analyses to support the operability assessment or to demonstrate that current operating limits are sufficient to protect 10 CFR 100 dose criteria.

PPL will pursue other approaches to demonstrate compliance to the criteria.

PPL is the only plant supported by Framatome ANP pump seizure dose calculations. Based on discussions with its other customers Framatome ANP believes that they are not impacted by the error reported by PPL.

Sincerely,

A handwritten signature in cursive script that reads "Ronnie L. Gardner".

Ronnie L. Gardner, Manager  
Site Operations and Regulatory Affairs

cc: M. C. Honcharik  
J. S. Wermiel  
F. M. Akstulewicz  
O. Tabatabai

IE19  
1/0